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S U M M A R Y
Objectives: The purpose of this study was to investigate serum levels of serum urokinase plasminogen
activation receptor (suPAR) during the ﬁrst week of febrile neutropenia and to demonstrate the
signiﬁcance of this biomarker in the diagnosis and follow-up of febrile neutropenic patients with
hematologic malignancies.
Methods: The study was performed between January 2011 and January 2012 at Karadeniz Technical
University, Turkey. For neutropenic patients with hematologic malignancies, the day before the onset of
fever and the ﬁrst day of the febrile neutropenia attack were taken as days 0 and 1, respectively. Blood
samples were obtained from patients with hematologic malignancies on days 0, 1, 3, 5, and 7. Sixty-eight
healthy volunteers were enrolled as the control group. suPAR levels were determined using an ELISA kit
following the manufacturer’s protocols. Twenty-six male and 14 female patients with hematologic
malignancies, the majority with acute/myeloid/lymphocytic leukemia, aged 19–78 years (mean 46.8
years), were included. Fifty febrile neutropenic attacks were investigated in these patients.
Results: The mean serum levels of the controls and suPAR 0 were 3.9  1.5 ng/ml and 5.8  2.7 ng/ml,
respectively. Serum levels of suPAR rose earlier than levels of C-reactive protein and procalcitonin. Serum
suPAR levels increased in patients with hematologic malignancies and were found to represent an important
serum biomarker for the early prediction of neutropenic fever. A decrease in serum suPAR levels was found to
be correlated with treatment response due to antibiotics in this patient group. There were signiﬁcant
differences in suPAR 1 levels between patients with documented infection and those with fever of unknown
origin in favor of the former. When the suPAR 1 results were analyzed using the receiver operating
characteristics (ROC) curve method, the optimum diagnostic cut-off point was 5.87 ng/ml, the area
underneath the ROC curve (AUC) was 0.81 (95% conﬁdence interval 0.68–0.91), sensitivity was 100%,
speciﬁcity was 69%, negative predictive value (NPV) was 100%, and positive predictive value (PPV) was 70%.
Conclusions: We conclude that suPAR is an important biomarker that can predict infections in the early
stage of febrile neutropenia with high sensitivity and NPV for patients with hematologic malignancies. It
is also advantageous since it shows the response to treatment with antibiotherapy in the early stage.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Infections are one of the main causes of mortality in febrile
neutropenic patients with hematologic malignancies.1,2 Since
clinical symptoms and ﬁndings in infections seen in neutropenic
hosts are indistinct and nonspeciﬁc and may sometimes be
identiﬁed late, the early and accurate diagnosis of infections in* Corresponding author. Tel.: +90 4623775632; fax: +90 4623775344.
E-mail address: eselkaya@yahoo.com (S. Kaya).
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http://dx.doi.org/10.1016/j.ijid.2013.04.004these patients is still problematic.1,2 Due to their low sensitivity,
many classic diagnostic techniques, such as culture, are not
practicable.2,3 Delays in diagnosis may lead to delays in treatment,
and this inevitably leads to an increase in mortality levels in this
patient group.2,3
Soluble urokinase plasminogen activation receptor (suPAR) is a
novel biomarker that exhibits an increase in levels during bacterial
and viral infections, particularly in the acute period; this could
therefore be used in the diagnosis and monitoring of many
infectious diseases.4–7 On the basis of the characteristics of suPAR,
our study aimed to investigate its contribution to early diagnosisses. Published by Elsevier Ltd. All rights reserved.
Table 1
Patient group demographic characteristics, chemotherapy protocols employed, and
documented infections
Patients
(n = 40)
Controls
(n = 68)
p-Value
Age, mean  SD (min–max) years 46.8  8.3
(19–78)
43.7  7.4
(17–80)
0.256
Gender 0.212
Male 26 (65%) 43 (63%)
Female 14 (35%) 25 (37%)
Underlying diseases
Acute myeloid leukemia 20 (50%)
Acute lymphocytic leukemia 13 (32.5%)
Multiple myeloma 5 (12.5%)
Chronic myeloid leukemia 1 (2.5%)
Chronic lymphocytic leukemia 1 (2.5%)
Chemotherapy protocol
Induction 30 (75%)
Consolidation 10 (25%)
Documented infections
Bacteremia 8/50 (16%)
Pneumonia 5/50 (10%)
Urinary tract infection 5/50 (10%)
Absent (fever of unknown origin) 32/50 (64%)
SD, standard deviation.
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Figure 1. suPAR CRP, and PCT serum levels by day (suPAR, soluble urokinase
plasminogen activation receptor; CRP, C-reactive protein; PCT, procalcitonin).
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neutropenic patients with hematologic malignancies.
2. Materials and methods
This observational cohort study was conducted in accordance
with the principles of the Declaration of Helsinki at the Karadeniz
Technical University, Faculty of Medicine Hospital, between
January 2011 and January 2012. Hospital ethics committee
approval was obtained before commencement. In neutropenic
patients with hematologic malignancies, the day before onset of
fever and the ﬁrst day of the febrile neutropenic attack were taken
as days 0 and 1, respectively. Blood samples were obtained from
patients with hematologic malignancies on days 0, 1, 3, 5, and 7.
Sixty-eight healthy volunteers were enrolled as the control group.
Levels of suPAR were determined using an ELISA kit (ViroGates
A/S, Denmark); the manufacturer’s protocols were followed. The
absorbance of samples was measured at 450 nm using a
VERSAmax Tunable Microplate Reader (Molecular Devices, CA,
USA); results were expressed in nanograms per milliliter. Levels of
C-reactive protein (CRP) were determined using a Dade Behring BN
II type device (Dade Behring, Germany); results were expressed in
milligrams per deciliter. Levels of procalcitonin (PCT) were
determined using a Brahms A00182 model device (Brahms,
France); results were expressed in nanograms per milliliter.
2.1. Statistical analysis
A descriptive statistical analysis was performed for all studied
variables. Data obtained in measurements of normal distribution
were analyzed using the Kolmogorov–Smirnov test. Data in
conformity with normal distribution were analyzed using the
Student’s t-test and those not conforming to normal distribution
using the Mann–Whitney U-test. Data obtained by measurements
are given as the mean  standard deviation. The area beneath the
receiver operating characteristics (ROC) curve was used to calculate
the discriminative ability of suPAR 1 to determine patients with
documented infection. Sensitivity, speciﬁcity, negative predictive
values (NPVs), and positive predictive values (PPVs) were calculated
for these markers on the basis of ROC curves. A p-value of <0.05 was
regarded as signiﬁcant.
3. Results
Forty patients with hematologic malignancies, 26 male and 14
female, with a mean age of 46.8  8.3 (range 19–78) years, were
included. Fifty febrile neutropenic attacks were investigated in these
patients. The demographic characteristics of the febrile neutropenic
patients with hematologic malignancies are shown in Table 1.
Mean serum levels of controls and suPAR 0 were 3.9  1.5 ng/ml
and 5.8  2.7 ng/ml, respectively (p < 0.001). Serum suPAR levels
reached a peak at the beginning of the febrile neutropenia attack,
rising earlier when compared to CRP and PCT, and decreased from the
end of the ﬁrst week, falling to pre-attack levels (Figure 1 and Table 2).Table 2
Comparison of serum biomarker levels on different days
Mean 
Day 0 Day 1 Day 3 
suPAR (ng/ml) 5.8  2.7 9.6  6.7 7.3  4.0 
CRP (mg/dl) 3.0  3.4 6.8  8.0 9.9  7.2 
PCT (ng/ml) 0.1  0.1 0.2  0.1 2.2  8.9 
Fever (8C) 38.4  0.4 37.9  1.0 
suPAR, serum urokinase plasminogen activation receptor; CRP, C-reactive protein; PCT
a a = day 0–day 1, b = day 0–day 3, c = day 0–day 5, d = day 0–day 7, e = day 1–dayClinical response was deﬁned as fever decreasing to under 38 8C and
improvement in physical examination ﬁndings for these patients. The
clinical response developed in parallel with the decrease in suPAR
levels. The rising trend in CRP and PCT was slower, and CRP continued
to rise even though the response to fever had developed. The
maximum suPAR, CRP, and PCT levels were 9.6  6.7 ng/ml,
12.0  11.5 mg/dl, and 2.2  8.9 ng/ml, these levels being reached
on days 1, 5, and 3 of febrile neutropenic attack, respectively.
As required by hospital protocols for the treatment of febrile
neutropenia attacks, patients were randomly given piperacillin/
tazobactam 4  4.5 g/day, ceftazidime 3  2 g/day, or cefepimep-Valuesa
Day 5 Day 7
6.2  2.8 6.4  4.2 a = 0.000, b = 0.001
12.0  11.5 8.8  9.7 a, b, c, d, e, f = 0.000
1.0  3.1 0.5  1.1 a, b, c, d = 0.000
37.5  0.9 37.2  0.9 e = 0.003
, procalcitonin.
 3, f = day 5–day 7.
Table 3
Levels of biomarkers in patients with documented infection and fever of unknown
origin
Documented
infection (n = 18)
Fever of unknown
origin (n = 32)
p-Value
suPAR (ng/ml)
suPAR 0 6.62  3.1 5.21  2.4 0.073
suPAR 1 12.34  6.2 7.62  6.4 <0.0001
suPAR 3 8.42  4.4 6.62  3.8 0.124
suPAR 5 6.56  3.7 6.07  2.0 0.585
suPAR 7 5.74  3.4 6.97  4.7 0.318
CRP (mg/dl)
CRP 0 3.40  4.0 2.78  3.0 0.535
CRP 1 7.41  8.9 6.27  7.4 0.624
CRP 3 10.52  7.9 9.44  6.7 0.606
CRP 5 13.20  12.6 10.76  10.8 0.465
CRP 7 10.35  11.5 7.41  8.1 0.294
PCT (ng/ml)
PCT 0 0.18  0.1 0.12  0.08 0.054
PCT 1 0.26  0.3 0.20  0.1 0.257
PCT 3 0.85  2.2 3.22  11.4 0.306
PCT 5 0.42  0.4 1.52  4.0 0.365
PCT 7 0.38  0.6 0.61  1.4 0.875
suPAR, soluble urokinase plasminogen activation receptor; CRP, C-reactive protein;
PCT, procalcitonin.
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brought under control with these therapies at the end of the third
day in 21 attacks, while in nine attacks the response was achieved
on the ﬁfth day. Since no response was still achieved with the
primary protocol on the ﬁfth day, treatment for 11 attacks was
modiﬁed to carbapenem, glycopeptide, and/or antifungal thera-
pies. While suPAR levels decreased to pre-attack levels in all 32
(100%) attacks in which a response to fever was achieved at the end
of the seventh day, they only returned to pre-attack levels in three
(33%) of the nine attacks in which the fever response was still not
achieved. Two patients died during the course of the attacks, while
the other attacks did not result in any mortality. One of the patients
who died had acute myeloid leukemia (AML) and the other had
acute lymphocytic leukemia (ALL). These were patients for whom a
response to fever was not achieved under antimicrobial treatment.
This study determined a signiﬁcant difference in suPAR 1 levels
between patients with documented infections and those with fever
of unknown origin in favor of the former. A comparison of serum
biomarker levels on the different days is shown in Table 3.
When the suPAR 1 results were analyzed using the ROC curve
method, the optimum diagnostic cut-off point was 5.87 ng/ml, thesuPAR
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Figure 2. Receiver operating characteristics of suPAR levels.area underneath the ROC curve (AUC) was 0.81 (95% conﬁdence
interval 0.68–0.91), sensitivity was 100%, speciﬁcity 69%, NPV
100%, and PPV 70% (Figure 2).
4. Discussion
suPAR is known to increase in several inﬂammatory and
infectious diseases, and the rise in serum level has a negative effect
on the clinical course.8–10 The most striking study to date regarding
suPAR in patients with hematologic malignancies is that by
Haastrup et al. involving 20 allogeneic stem cell recipients.11 In
that study, pre-transplant suPAR values were higher than those of
the control group; suPAR values were monitored weekly for 1
month post-transplant. There was a pronounced rise in suPAR
values on the ﬁrst day, particularly with the administration of anti-
thymocyte globulin during transplant, and that rise was a
predictive marker of a high mortality. On the seventh day post-
transplant, suPAR returned to pre-transplant levels. Yılmaz et al.
revealed the diagnostic and prognostic value of suPAR in patients
with Crimean-Congo hemorrhagic fever (CCHF).12 Diagnostically,
and in contrast to the study of Yılmaz et al., the systematic review
by Backes et al. emphasizes that suPAR levels do not make a major
contribution in the diagnosis of patients with sepsis, but that they
are important in terms of determining the prognosis.13 Serum
suPAR levels were signiﬁcantly higher in patients with infection
compared to the controls. In our study, serum suPAR levels were
also higher in patients with hematologic malignancies compared
to the controls. In addition, suPAR levels after febrile neutropenia
were higher than those before febrile neutropenia in patients with
hematologic malignancies. This is thought, in all probability, to be
correlated with infections developing during the course of febrile
neutropenia. The serum levels rising from the ﬁrst day of empiric
therapy and then decreasing in the days that follow, returning to
initial values at the end of the ﬁrst week, is noteworthy. At the end
of the ﬁrst week, a fever response and clinical response were
observed in all those patients whose serum suPAR levels had
returned to initial values.
Unfortunately, most of the infections seen in this group of
patients could not be documented clinically or by the laboratory.
suPAR had a high sensitivity and NPV for distinguishing infections
from other causes of fever in hematologic patients. As shown in the
current study, suPAR 1 levels were signiﬁcantly higher in patients
with documented infection than in those with fever of unknown
origin. This may be due to some other non-infectious causes of
fever in these patients.
CRP and PCT have also been investigated for the purpose of
determining their place in the diagnosis and treatment follow-up
in febrile neutropenic patients with hematologic malignancies.
There have been many studies of these markers in both child and
adult age groups, and all studies have shown them to be beneﬁcial
in these patient groups.14–16 However, CRP levels decreased during
the late period in patients who had developed a response to
antibiotherapy, making CRP less useful for the monitoring of such
patients. In contrast, our study showed PCT to be a useful
biomarker that can be used to monitor such patients. However,
neither CRP nor PCT had any predictive value for the early
diagnosis of documented infections.
Although there are no perfect biomarkers that can predict all
infections in the early stage of a febrile neutropenic attack, suPAR is
a very important biomarker with high sensitivity and NPV for
patients with hematologic malignancies. It is also advantageous
since it shows the response to treatment under antibiotherapy in
the early stage. As seen in our study, it is an easily available
biomarker that can assist in clinical decision-making using serial
measurements in these patients. CRP and PCT are not as useful as
suPAR for the early diagnosis of infections in this patient
S. Kaya et al. / International Journal of Infectious Diseases 17 (2013) e1056–e1059 e1059population. We believe that our study will encourage further large-
scale studies in this area.
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